The potential effectiveness of probiotics in reducing multiple sclerosis progression in preclinical and clinical studies: A worldwide systematic review and meta-analysis.
<h4>Background and objective</h4>Multiple Sclerosis (MS) is an immune-mediated disease characterized by nerve cell inflammation and demyelination. The effectiveness of probiotics in reducing inflammatory damage in MS. Therefore, the aim of this systematic review and meta-analysis was the...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0319755 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850198830981578752 |
|---|---|
| author | Zahra Zangeneh Mosayeb Rostamian Hamid Motamedi Amirhooshang Alvandi Ramin Abiri |
| author_facet | Zahra Zangeneh Mosayeb Rostamian Hamid Motamedi Amirhooshang Alvandi Ramin Abiri |
| author_sort | Zahra Zangeneh |
| collection | DOAJ |
| description | <h4>Background and objective</h4>Multiple Sclerosis (MS) is an immune-mediated disease characterized by nerve cell inflammation and demyelination. The effectiveness of probiotics in reducing inflammatory damage in MS. Therefore, the aim of this systematic review and meta-analysis was the potential effectiveness of probiotics in reducing Multiple Sclerosis progression in preclinical and clinical studies.<h4>Methods</h4>PubMed, Scopus, Cochrane, and Google Scholar databases were searched using multiple relevant keywords, and screening was carried out based on the inclusion/exclusion criteria from January 2004 to August 16, 2024.<h4>Results</h4>Based on our criteria, 269 papers were obtained, and after omission of unsuitable articles, 23 full-text articles consisting of 17 animal studies and six human models were selected. It was concluded that in an experimental autoimmune encephalomyelitis (EAE) animal model, probiotics such as Bifidobacterium, Prevotella, and Lactobacillus can decrease the T helper 1 (Th1)/Th17 ratio while inducing interferon gamma (IFN-γ) and interleukin (IL)-17 levels. In all cases, probiotics can modulate immune cells and cytokines and consequently decrease EAE signs and symptoms. In all human studies, single or multiple probiotics decreased the severity of disease and changed the gut microbiota population.<h4>Conclusion</h4>Our results showed that probiotics can control the development of MS by reducing inflammatory conditions, and may have beneficial effects in the prevention and treatment of MS. |
| format | Article |
| id | doaj-art-0bc43af34e2f4343afa8a6979c0c2b0f |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-0bc43af34e2f4343afa8a6979c0c2b0f2025-08-20T02:12:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01204e031975510.1371/journal.pone.0319755The potential effectiveness of probiotics in reducing multiple sclerosis progression in preclinical and clinical studies: A worldwide systematic review and meta-analysis.Zahra ZangenehMosayeb RostamianHamid MotamediAmirhooshang AlvandiRamin Abiri<h4>Background and objective</h4>Multiple Sclerosis (MS) is an immune-mediated disease characterized by nerve cell inflammation and demyelination. The effectiveness of probiotics in reducing inflammatory damage in MS. Therefore, the aim of this systematic review and meta-analysis was the potential effectiveness of probiotics in reducing Multiple Sclerosis progression in preclinical and clinical studies.<h4>Methods</h4>PubMed, Scopus, Cochrane, and Google Scholar databases were searched using multiple relevant keywords, and screening was carried out based on the inclusion/exclusion criteria from January 2004 to August 16, 2024.<h4>Results</h4>Based on our criteria, 269 papers were obtained, and after omission of unsuitable articles, 23 full-text articles consisting of 17 animal studies and six human models were selected. It was concluded that in an experimental autoimmune encephalomyelitis (EAE) animal model, probiotics such as Bifidobacterium, Prevotella, and Lactobacillus can decrease the T helper 1 (Th1)/Th17 ratio while inducing interferon gamma (IFN-γ) and interleukin (IL)-17 levels. In all cases, probiotics can modulate immune cells and cytokines and consequently decrease EAE signs and symptoms. In all human studies, single or multiple probiotics decreased the severity of disease and changed the gut microbiota population.<h4>Conclusion</h4>Our results showed that probiotics can control the development of MS by reducing inflammatory conditions, and may have beneficial effects in the prevention and treatment of MS.https://doi.org/10.1371/journal.pone.0319755 |
| spellingShingle | Zahra Zangeneh Mosayeb Rostamian Hamid Motamedi Amirhooshang Alvandi Ramin Abiri The potential effectiveness of probiotics in reducing multiple sclerosis progression in preclinical and clinical studies: A worldwide systematic review and meta-analysis. PLoS ONE |
| title | The potential effectiveness of probiotics in reducing multiple sclerosis progression in preclinical and clinical studies: A worldwide systematic review and meta-analysis. |
| title_full | The potential effectiveness of probiotics in reducing multiple sclerosis progression in preclinical and clinical studies: A worldwide systematic review and meta-analysis. |
| title_fullStr | The potential effectiveness of probiotics in reducing multiple sclerosis progression in preclinical and clinical studies: A worldwide systematic review and meta-analysis. |
| title_full_unstemmed | The potential effectiveness of probiotics in reducing multiple sclerosis progression in preclinical and clinical studies: A worldwide systematic review and meta-analysis. |
| title_short | The potential effectiveness of probiotics in reducing multiple sclerosis progression in preclinical and clinical studies: A worldwide systematic review and meta-analysis. |
| title_sort | potential effectiveness of probiotics in reducing multiple sclerosis progression in preclinical and clinical studies a worldwide systematic review and meta analysis |
| url | https://doi.org/10.1371/journal.pone.0319755 |
| work_keys_str_mv | AT zahrazangeneh thepotentialeffectivenessofprobioticsinreducingmultiplesclerosisprogressioninpreclinicalandclinicalstudiesaworldwidesystematicreviewandmetaanalysis AT mosayebrostamian thepotentialeffectivenessofprobioticsinreducingmultiplesclerosisprogressioninpreclinicalandclinicalstudiesaworldwidesystematicreviewandmetaanalysis AT hamidmotamedi thepotentialeffectivenessofprobioticsinreducingmultiplesclerosisprogressioninpreclinicalandclinicalstudiesaworldwidesystematicreviewandmetaanalysis AT amirhooshangalvandi thepotentialeffectivenessofprobioticsinreducingmultiplesclerosisprogressioninpreclinicalandclinicalstudiesaworldwidesystematicreviewandmetaanalysis AT raminabiri thepotentialeffectivenessofprobioticsinreducingmultiplesclerosisprogressioninpreclinicalandclinicalstudiesaworldwidesystematicreviewandmetaanalysis AT zahrazangeneh potentialeffectivenessofprobioticsinreducingmultiplesclerosisprogressioninpreclinicalandclinicalstudiesaworldwidesystematicreviewandmetaanalysis AT mosayebrostamian potentialeffectivenessofprobioticsinreducingmultiplesclerosisprogressioninpreclinicalandclinicalstudiesaworldwidesystematicreviewandmetaanalysis AT hamidmotamedi potentialeffectivenessofprobioticsinreducingmultiplesclerosisprogressioninpreclinicalandclinicalstudiesaworldwidesystematicreviewandmetaanalysis AT amirhooshangalvandi potentialeffectivenessofprobioticsinreducingmultiplesclerosisprogressioninpreclinicalandclinicalstudiesaworldwidesystematicreviewandmetaanalysis AT raminabiri potentialeffectivenessofprobioticsinreducingmultiplesclerosisprogressioninpreclinicalandclinicalstudiesaworldwidesystematicreviewandmetaanalysis |